Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Decensi

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2006
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancerU Veronesi, L Mariani, A Decensi, et al.
Ecancermedicalscience|January 26, 2012
The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trialM Lazzeroni, D Macis, A Decensi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 6, 2001
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patientsM Dowsett, N J Bundred, A Decensi, et al.
Journal of Cellular Biochemistry|January 5, 2000
Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trialS Bruno, R Torrisi, M Costantini, et al.
British Journal of Cancer|October 26, 2013
The effect of metformin on apoptosis in a breast cancer presurgical trialM Cazzaniga, A DeCensi, G Pruneri, et al.
The Pharmacogenomics Journal|March 24, 2010
Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention TrialD Serrano, M Lazzeroni, C-F Zambon, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 25, 2000
Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end pointA Decensi, R Torrisi, S Bruno, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 6, 2001
Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancerA Decensi, H Johansson, R Miceli, et al.
British Journal of Cancer|April 13, 2013
Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotypeM Lazzeroni, A Guerrieri-Gonzaga, E Botteri, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2002
Rationale for a study adding tamoxifen to HRTN Rotmensz, A Decensi, P Maisonneuve, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2006
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancerU Veronesi, L Mariani, A Decensi, et al.
Ecancermedicalscience|January 26, 2012
The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trialM Lazzeroni, D Macis, A Decensi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 6, 2001
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patientsM Dowsett, N J Bundred, A Decensi, et al.
Journal of Cellular Biochemistry|January 5, 2000
Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trialS Bruno, R Torrisi, M Costantini, et al.
British Journal of Cancer|October 26, 2013
The effect of metformin on apoptosis in a breast cancer presurgical trialM Cazzaniga, A DeCensi, G Pruneri, et al.
The Pharmacogenomics Journal|March 24, 2010
Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention TrialD Serrano, M Lazzeroni, C-F Zambon, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 25, 2000
Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end pointA Decensi, R Torrisi, S Bruno, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 6, 2001
Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancerA Decensi, H Johansson, R Miceli, et al.
British Journal of Cancer|April 13, 2013
Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotypeM Lazzeroni, A Guerrieri-Gonzaga, E Botteri, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2002
Rationale for a study adding tamoxifen to HRTN Rotmensz, A Decensi, P Maisonneuve, et al.
Pageof 10